- Home
- CCEC vs PHVS Comparison
CCEC vs PHVS Comparison
Compare CCEC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- PHVS
- Stock Information
- Founded
- CCEC 2007
- PHVS 2015
- Country
- CCEC Greece
- PHVS Netherlands
- Employees
- CCEC N/A
- PHVS N/A
- Industry
- CCEC Marine Transportation
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- CCEC Consumer Discretionary
- PHVS Health Care
- Exchange
- CCEC Nasdaq
- PHVS Nasdaq
- Market Cap
- CCEC 1.1B
- PHVS 1.0B
- IPO Year
- CCEC 2007
- PHVS 2021
- Fundamental
- Price
- CCEC $18.75
- PHVS $18.36
- Analyst Decision
- CCEC Buy
- PHVS Strong Buy
- Analyst Count
- CCEC 1
- PHVS 5
- Target Price
- CCEC $22.00
- PHVS $40.60
- AVG Volume (30 Days)
- CCEC 16.3K
- PHVS 47.5K
- Earning Date
- CCEC 01-31-2025
- PHVS 11-13-2024
- Dividend Yield
- CCEC 3.20%
- PHVS N/A
- EPS Growth
- CCEC N/A
- PHVS N/A
- EPS
- CCEC 0.85
- PHVS N/A
- Revenue
- CCEC $447,305,000.00
- PHVS N/A
- Revenue This Year
- CCEC $17.05
- PHVS N/A
- Revenue Next Year
- CCEC $5.68
- PHVS N/A
- P/E Ratio
- CCEC $75.99
- PHVS N/A
- Revenue Growth
- CCEC 29.66
- PHVS N/A
- 52 Week Low
- CCEC $14.45
- PHVS $15.21
- 52 Week High
- CCEC $20.26
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- CCEC N/A
- PHVS 48.93
- Support Level
- CCEC N/A
- PHVS $15.21
- Resistance Level
- CCEC N/A
- PHVS $19.59
- Average True Range (ATR)
- CCEC 0.00
- PHVS 1.39
- MACD
- CCEC 0.00
- PHVS -0.02
- Stochastic Oscillator
- CCEC 0.00
- PHVS 67.31
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the leading platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.